The non-Hodgkin's lymphoma is a general category of lymphoma. There are many subtypes that fall into this category. Diffuse large B-cell lymphoma and follicular lymphoma are among the most common subtypes. The other general category of lymphoma is Hodgkin lymphoma. Advances in the diagnosis and treatment of non-Hodgkin lymphoma have helped improve the prognosis for people with this disease.
Access full Report @ https://www.databridgemarketresearch.com/reports/global-non-hodgkin-lymphoma-diagnostics-market
Data Bridge Market Research analyses that the India produced water treatment market is expected to grow at a CAGR of 8.5% from 2023 to 2030 and is expected to reach USD 20,210.58 million by 2030. The rise in increase in the geriatric population, the launch of new products for non-Hodgkin lymphoma diagnostics and the reimbursement policy for Non-Hodgkin Cancer Diagnostics is expected to propel the market's growth
Key Findings of the Study
- The global non-Hodgkin lymphoma diagnostics market was valued at USD 10,500.00 million in 2022 and is expected to reach USD 20,210.58 million by 2030, registering a CAGR of 8.5% during the forecast period of 2023 to 2030
- Advancement in artificial intelligence in the diagnosis of non-Hodgkin lymphoma is expected to drive the market growth
- The imaging test type segment is expected to grow because of easy adaptability and low cost of implementation
- An increase in awareness regarding non-Hodgkin lymphoma acting as a major driver for the demand for non-Hodgkin lymphoma diagnosis
- Technological advancements and rising government funded projects for healthcare infrastructure are expected to drive the market growth
RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
Preventive health check-up is preventive actions performed for the initial detection of cancer disease, and also rising preference for preventive health check-ups provide a safeguard against likely exposure to any disease in the future.
Awareness to promote screening is the most important component of cancer prevention. The check-up is comprised of the identification of cancer and examinations of risk factors to limit loss at an early stage.
Preventive cancer check-up is performed with the help of various diagnostic tests, including ultrasound, biopsy, immunohistochemistry, antibody test, and blood test (TSH, T3, T4, and TSI), among others.
Furthermore, these days the demand for preventive cancer diagnostics has increased due to increasing concern toward the disease non-Hodgkin lymphoma in the population worldwide, which boosts the demand in the global non-Hodgkin lymphoma diagnostics market
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, and Pricing in USD
|
|
Segments Covered
|
By Test Type (Imaging, Biopsy, Immunohistochemistry, Biomarker Test, Genetic Test, Cytogenetics, Lumbar Puncture (Spinal Tap), Blood Test, and Cytochemistry), Cancer Stage (Stage IV, Stage III, Stage II, Stage I, and Stage 0), Tumor Type (Aggressive Lymphomas, and Indolent Lymphomas), Product (Instrument Based Products, Platform Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Rest of Middle East and Africa
|
|
Market Players Covered
|
CANON MEDICAL SYSTEMS CORPORATION (Tochigi Prefecture, Japan), Koninklijke Philips N.V.(Amsterdam, Netherland), Siemens Healthcare GmbH (Erlangen, Germany), Danaher (Washington U.S.), Bio-Rad Laboratories, Inc (California, U.S.), General Electric Company (Massachusetts, U.S.), Sysmex Corporation (Hyogo, Japan), Grail (California, U.S.), F. Hoffmann-La Roche (Basel, Switzerland), Neusoft Corporation (Shenyang, China), Agilent Technologies, Inc. (California, U.S.), NeoGenomics Laboratories(Florida, U.S), Hologic, Inc(Massachusetts, U.S.), Integrated DNA Technologies, Inc., CENTOGENE N.V. (Rostock, Germany), Merit Medical Systems(Utah, U.S.), Invitae Corporation (California, U.S.), PerkinElmer Inc.(Massachusetts, U.S.), QIAGEN (California, U.S.), and GeneDx, LLC(Connecticut, U.S) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
The global non-Hodgkin lymphoma diagnostics market is categorized into eight notable segments, which are based on the test type, cancer stage, tumor type, product, technology, application, end users, and distribution channel
On the basis of test type, the global non-Hodgkin lymphoma diagnostics market is segmented into imaging, biopsy, immunohistochemistry, biomarker test, genetic test, cytogenetics, lumbar puncture (spinal tap), blood test, cytochemistry, and others.
In 2023, the imaging segment is expected to dominate the market due to the primary test recommended for preliminary testing
In 2023, the imaging segment is expected to dominate the market due to the primary test recommended for preliminary testing. The imaging segment is expected to reach the highest CAGR of 11.2% in the forecast period of 2023-2030.
- On the basis of test type, the global non-Hodgkin lymphoma diagnostics market is segmented into imaging, biopsy, immunohistochemistry, biomarker test, genetic test, cytogenetics, lumbar puncture (spinal tap), blood test, cytochemistry, and others. In 2023, the imaging segment is expected to dominate in the global non-Hodgkin lymphoma diagnostics market, as imaging is the primary test recommended for preliminary testing. As imaging looks for cancer in its early stages and a person has no symptoms
- On the basis of the cancer stage, the global non-Hodgkin lymphoma diagnostics market is segmented into stage 0, I, II, III, and IV. In 2023, the stage IV segment is expected to dominate in the global non-Hodgkin lymphoma diagnostics market as the cancer stage tells where a cancer is located and its size and how far it has grown into nearby tissues. The clinical stage is an estimate of the extent of cancer based on the results of diagnostics
- On the basis of tumor type, the global non-Hodgkin lymphoma diagnostics market is segmented into aggressive lymphomas and indolent lymphomas. In 2023, the aggressive lymphomas segment is expected to dominate in the global non-Hodgkin lymphoma diagnostics market as it is a rare type of non-Hodgkin lymphoma and is a high-grade lymphoma that affects blood cells called T cells
- On the basis of product, the global non-Hodgkin lymphoma diagnostics market is segmented into instrument based products, platform based products, kits and reagents, and other consumables. In 2023, the instrument based products segment is expected to dominate in the global non-Hodgkin lymphoma diagnostics market due to increasing technical advancements in non-Hodgkin lymphoma diagnostics
- On the basis of technology, the global non-Hodgkin lymphoma diagnostics market is segmented into fluorescent in situ hybridization, next generation sequencing, fluor immunoassay, comparative genomic hybridization, immunohistochemically, and others. In 2023, the fluorescent in situ hybridization segment is expected to dominate in the non-Hodgkin lymphoma diagnostics market as it is the most convincing technique for locating the specific DNA sequences, diagnosis of genetic diseases, gene mapping, and identification of novel oncogenes or genetic aberrations contributing to various types of cancers
- On the basis of application, the global non-Hodgkin lymphoma diagnostics market is segmented into screening, diagnostic and predictive, prognostic, and research. In 2023, the screening segment is expected to dominate in the global non-Hodgkin lymphoma diagnostics market as it is the most convincing technique used to find cancer in people who have no symptoms, and regular screening gives the best chance of finding cancer early when it's small and before it has spread
- On the basis of end user, the global non-Hodgkin lymphoma diagnostics market is segmented into hospitals, diagnostic centers, cancer research centers, academic institutes, ambulatory surgical centers, and others.
In 2023, the hospitals segment is expected to hold the largest share of the end user segment in the global non-Hodgkin lymphoma diagnostics market.
In 2023, the hospitals segment is expected to dominate the market because hospitals enable the facilitation of robust, on-time, cost-effective, and high quality diagnostic care and services in a safe healthcare environment. The hospitals segment is expected to grow with a CAGR of 10.7% in the forecast period of 2023 to 2030.
- On the basis of distribution channel, the global non-Hodgkin lymphoma diagnostics market is segmented into direct tender, retail sales, and others. In 2023, the direct tender segment is expected to dominate the global non-Hodgkin lymphoma diagnostics market as they are the primary source of procurement of reagents, consumables, devices, and accessories by healthcare organizations and diagnostic labs. With the increasing cost of healthcare, healthcare providers are focusing on better services for customers and reducing the overall cost. The procurement of products through direct tender is highly cost effective for healthcare providers
Major Players
Data Bridge Market Research recognizes the following companies as the major market players in the Global Non-Hodgkin Lymphoma Diagnostics market. They are CANON MEDICAL SYSTEMS CORPORATION, Koninklijke Philips N.V., Siemens Healthcare GmbH, Danaher., Bio-Rad Laboratories, Inc., General Electric Company, Sysmex Corporation, Grail, F. Hoffmann-La Roche, Neusoft Corporation, Agilent Technologies, Inc., NeoGenomics Laboratories, Hologic, Inc, Integrated DNA Technologies, Inc., CENTOGENE N.V., Merit Medical Systems, Invitae Corporation, PerkinElmer Inc., QIAGEN, and GeneDx, LLC among others
Market Developments
- In November 2022, Danaher announced that it had entered a strategic partnership with Duke University to form its first Danaher Beacon for Gene Therapy Innovation. The program invests in product innovation to advance external R&D strategies with a focus on genomic medicines, precision diagnostics, next-generation bio manufacturing, human systems, and data sciences
- In August 2022, Bio-Rad Laboratories Inc. acquired Curiosity Diagnostics, a Poland-based developer of innovative technology solutions for the medical diagnostic and healthcare markets. This has helped the company to increase its product portfolio and global presence in the market
- In June 2022, Agilent Technologies Inc. announced that previously CE-IVD marked instruments, kits, and reagents were released as IVDR Class A on May 26, 2022, in compliance with the new EU IVDR regulation
- In March 2021, Hologic, Inc. announced that the company had acquired Diagenode, a privately held European developer and manufacturer of molecular diagnostic assays and epigenetics products. This further strengthens the molecular diagnostics business in the global market
- In August 2020, Siemens Healthcare GmbH entered into an agreement with Varian Medical Systems, Inc. With this acquisition, Siemens Healthcare has helped in developing advanced solutions to treat cancer and strengthen its position in the healthcare industry
Regional Analysis
Geographically, the country covered in the global non-Hodgkin lymphoma diagnostics market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, and UAE) Egypt, Israel, Rest of Middle East) and Africa
As per Data Bridge Market Research analysis:
Global non-Hodgkin lymphoma diagnostics market is expected to grow at a CAGR of 8.5% due to rise in the increase in the geriatric population, the launch of new products for non-Hodgkin lymphoma diagnostics and the reimbursement policy for non-Hodgkin cancer diagnostics.
For more detailed information about the global non-Hodgkin lymphoma diagnostics market, click here - https://www.databridgemarketresearch.com/reports/global-non-hodgkin-lymphoma-diagnostics-market
